STTCOMP MDC, FA Long Medlab Clinical SP 0.185c MC $29 mill Cash...

STTCOMP MDC, FA Long
Medlab Clinical
SP 0.185c
MC $29 mill
Cash $3 mill

1. MDC floated to the Australian Stock Exchange within 3 years of starting research operations, ASX: MDC.
2. MDC were lawfully granted a research licence to develop new medicines from cannabis here in Australia.
3. MDC developed 2 probiotic strains bonded to an amino acid that biochemically activate the production of lean body mass in the human body.
4. MDC showed in animal studies that several specifically selected probiotics in the right combination can rescue non alcoholic fatty liver disease (NAFLD).
5. MDC engineered a remarkable small particle absorption platform called NanoCelle for drug delivery that is unique in every way.
6. MDC developed prototypes for safer more effective statins, insulin and testosterone.
7. Our human research into medication resistant Depressed patients shows we can improve patient models using a unique blend of probiotics and minerals beyond that of an SSRI.
8. Nutraceutical commercialisation is well underway with global interest.
9. In 2016, MDC's human trial agenda increases, as well as our expansion of the nutraceutical business.
   Medalb's aim is simple, expand the practitioner's toolbox to offer greater therapeutic choice when treating or managing patients with chronic diseases.

Recently Medlab shipped its first order to China, and with its suite of 13 products expanding by another 10 by June sales
should expand at an accelerated rate.